Clinical trial
A Phase Ⅰ Study Evaluating Safety and Efficacy of C-CAR088 Treatment in Subjects With Relapsed or Refractory Multiple Myeloma
NCT03815383 is registered in ClinicalTrials.gov with The First Affiliated Hospital with Nanjing Medical University as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase Ⅰ Study Evaluating Safety and Efficacy of C-CAR088 Treatment in Subjects With Relapsed or Refractory Multiple Myeloma
- Lead sponsor
- The First Affiliated Hospital with Nanjing Medical University
- Phase
- Phase 1
- Overall status
- Unknown status
- Start date
- April 11, 2019
- Completion date
- April 30, 2021
- Enrollment
- 12 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
relapsed or refractory multiple myeloma